Study record managers: refer to the Data Element Definitions if submitting registration or results information.
|1||NCT01358877||Active, not recruiting
|A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer||
||Industry / Other||
||4804||All||18 Years and older (Adult, Older Adult)||NCT01358877||BO25126
|APHINITY||November 8, 2011||December 19, 2016||December 1, 2023||May 24, 2011||November 29, 2018||January 5, 2018||